Diagnosis and management of Duchenne muscular dystrophy

Major Points:

1. Introduction to DMD: Duchenne muscular dystrophy is a lethal X-linked recessive neuromuscular disorder caused by mutations in the dystrophin gene. It leads to progressive muscular damage, degeneration, and eventually death due to cardiac or respiratory compromise.
2. Need for Update: The report emphasizes the need for updated care considerations due to improved patient survival, advances in diagnostic and therapeutic strategies, and emerging genetic and molecular therapies.
3. Multidisciplinary Care: The report stresses the importance of multidisciplinary care involving various subspecialties to improve patient outcomes and quality of life.
4. New Topics: The updated care considerations introduce three new topics—primary care and emergency management, endocrine management, and transitions of care across the lifespan.
5. Diagnosis and Management: The report covers diagnosis, neuromuscular management, rehabilitation management, endocrine management (including growth, puberty, and adrenal insufficiency), and gastrointestinal management (including nutrition and dysphagia).

Findings:

1. Shift in Approach: There is a shift towards more anticipatory diagnostic and therapeutic strategies to prevent, identify, and treat predictable and potentially modifiable disease complications.
2. Quality of Life: An increasing emphasis is being placed on improving the quality of life and psychosocial management of DMD patients.
3. Transitions of Care: There is an urgent need to coordinate and improve patient transitions from childhood to adulthood.
4. Efficacy of Therapies: New information is available on the efficacy, side-effects, and limitations of glucocorticoids, which are commonly used in DMD management.
5. Methodology: The guidance in this update is not conventionally evidence-based due to the rarity of the disease. Expert opinions and existing scientific literature form the basis of the recommendations.